Homoharringtonine, aclacinomycin, cyctarabine and G-CSF (HCAG) regimen in the treatment of newly diagnosed elderly acute myeloid leukemia

A multi-center, randomized, prospective clinical study of homoharringtonine, aclacinomycin, cyctarabine and G-CSF (HCAG) regimen in the treatment of newly diagnosed elderly acute myeloid leukemia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-16008809

Enrollment

Unknown

Registered

2016-07-08

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Group A:DA regimen

Group B:HCAG regimen

Eligibility

Sex/Gender

All

Age

55 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed AML patients by both morphology and immunology; 2. Rule out APL by morphology and molecular; 3. To be aged 55~71 years; 4. All patients will be evaluated by the researchers to see if they are qualified for this trial; 5. Signed written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with ejection fraction =2.

Design outcomes

Primary

Measure	Time frame
Complete Remission Rate;Partial Remission Rate;Overall Survival;Progression Free Survival;Relapse Free Survival;	—

Countries

China

Contacts

Public ContactJunmin Li

Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology

lijunmin@medmail.com.cn+86 021-64370045-665258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026